Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
AstraZeneca
Dow
Citi
US Department of Justice
Daiichi Sankyo
Julphar
Fish and Richardson
Teva

Generated: July 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020825

« Back to Dashboard

NDA 020825 describes GEODON, which is a drug marketed by Pfizer and Pfizer Inc and is included in three NDAs. It is available from seven suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the GEODON profile page.

The generic ingredient in GEODON is ziprasidone mesylate. There are twenty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ziprasidone mesylate profile page.
Summary for 020825
Tradename:GEODON
Applicant:Pfizer
Ingredient:ziprasidone hydrochloride
Patents:2
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020825
Suppliers and Packaging for NDA: 020825
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825 NDA Roerig 0049-0052 N 0049-0052-60
GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825 NDA Roerig 0049-0052 N 0049-0052-80

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 20MG BASE
Approval Date:Feb 5, 2001TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:May 27, 2019Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Dec 18, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF BIPOLAR DISORDER

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 40MG BASE
Approval Date:Feb 5, 2001TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:May 27, 2019Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 020825

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-003 Feb 5, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Federal Trade Commission
Teva
Healthtrust
Daiichi Sankyo
Fish and Richardson
UBS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.